借力推动前列腺癌 CAR-T 细胞治疗进展
Piggybacking toward Progress for CAR T-Cell Therapy in Prostate Cancer.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
前列腺癌患者中单核细胞衍生树突状细胞表型受损：与健康供者的表型比较
英文原题：Impaired monocyte-derived dendritic cell phenotype in prostate cancer patients: A phenotypic comparison with healthy donors.
查看英文原题
Impaired monocyte-derived dendritic cell phenotype in prostate cancer patients: A phenotypic comparison with healthy donors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
DC 疫苗效果有限可能归因于其表型特征的受损。这些观察结果表明，从癌症患者血液样本中生成的 Mo-DC 的次优特征可能导致 DC 疫苗效果有限。因此，本研究强调了需要替代策略来增强 Mo-DC 的特性，以实现更有效的癌症免疫治疗。
研究思路结论见上方概要
背景
树突状细胞（DCs）在免疫中发挥关键作用。尽管临床试验中成功有限，但单核细胞衍生树突状细胞（Mo-DCs）癌症疫苗的研究仍在进行中。本研究聚焦于从前列腺癌（PCA）患者中生成的Mo-DCs，并将其与健康供体（HD-DCs）的DCs进行比较。
方法
从PCA患者样本中分离出Mo-DCs，并将其表型与HD-DCs进行比较。评估的关键参数包括单核细胞计数、CD14表达以及成熟标志物（HLA-DR、CD80、CD86）的水平。
结果
与健康样本相比，PCA样本的单核细胞计数显著降低，CD14表达减少（p ⟨ 0.0001）。此外，与HD-DC相比，PCA-DC的成熟标志物表达水平显著降低，包括HLA-DR、CD80和CD86（分别为p = 0.123、p = 0.884和p = 0.309）。
展开英文摘要原文
BACKGROUND
Dendritic cells (DCs) play a crucial role in immunity. Research on monocyte-derived DCs (Mo-DCs) cancer vaccines is in progress despite limited success in clinical trials. This study focuses on Mo-DCs generated from prostate cancer (PCA) patients, comparing them with DCs from healthy donors (HD-DCs).
METHODS
Mo-DCs were isolated from PCA patient samples, and their phenotype was compared to HD-DCs. Key parameters included monocyte count, CD14 expression, and the levels of maturation markers (HLA-DR, CD80, CD86) were assessed.
RESULTS
PCA samples exhibited a significantly lower monocyte count and reduced CD14 expression compared to healthy samples (p ⟨ 0.0001). Additionally, PCA-DCs expressed significantly lower levels of maturation markers, including HLA-DR, CD80, and CD86, when compared to HD-DCs (p = 0.123, p = 0.884, and p = 0.309, respectively).
CONCLUSION
The limited success of DC vaccines could be attributed to impaired phenotypic characteristics. These observations suggest that suboptimal characteristics of Mo-DCs generated from cancer patient blood samples might contribute to the limited success of DC vaccines. Consequently, this study underscores the need for alternative strategies to enhance the features of Mo-DCs for more effective cancer immunotherapies.
论文信息
- 作者
- Bakhshi P、Nourizadeh M、Sharifi L、Nowroozi MR、Mohsenzadegan M、Farajollahi MM
- 单位
- Department of Medical Biotechnology, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.Iran
- 文献类型
- 非美国政府资助研究
- 期刊
- Cancer reports (Hoboken, N.J.)2024 Feb
- 原文标识
- PubMed 38351552 · DOI 10.1002/cnr2.1996
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →